E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033128 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10016180 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10061344 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare progression-free survival (PFS) of patients randomised to selected chemotherapy only or to selected chemotherapy plus bevacizumab. |
|
E.2.2 | Secondary objectives of the trial |
Objective response rate (ORR) - by RECIST and CA-125 response criteria (responders) - by RECIST only (RECIST responders) - by CA-125 response criteria only (CA-125 responders). Biological progression-free interval (PFIBIO) - by serum CA-125 and assessed according to the GCIG criteria Overall survival (OS) Quality of life (QOL) - QOL and symptom control will be assessed using EORTC QLQ-C30, QLQ-OV28, Hospital Anxiety Depression Scale (HADS), FACT/NCCN Ovarian Symptom Index (FOSI) and symptom questionnaires. Safety and tolerability. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patients awareness and willingness to comply with the study requirements. 2. Patients >= 18 years of age. 3. Histologically confirmed and documented disease. The following histological types are eligible: adenocarcinoma NOS clear cell adenocarcinoma endometriod adenocarcinoma malignant Brenner`s tumour mixed epithelial carcinoma mucinous adenocarcinoma serous adenocarcinoma transitional cell carcinoma undifferentiated carcinoma. 4. Patients must have platinum-resistant disease, (defined as progression within <6 months of platinum therapy) 5. Patients must have disease that is measurable according to RECIST or assessable according to the GCIG CA-125 criteria and require chemotherapy treatment. 6. ECOG PS 02. 7. Life expectancy of >= 12 weeks. |
|
E.4 | Principal exclusion criteria |
Cancer-related 1. Patients whose disease was refractory to their previous treatment. Refractory disease is defined by those patients who progressed during the preceding treatment. 2. Non-epithelial, including malignant mixed M�llerian tumours. 3. Ovarian tumours with low malignant potential (i.e. borderline tumours). 4. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer Prior, current or planned treatment: 5. Previous treatment with >2 chemotherapy regimens. 6. Any prior radiotherapy to the pelvis or abdomen. 7. Surgery (including open biopsy) within 4 weeks prior to the start of study, or anticipation of the need for major surgery during study treatment. 8. Minor surgical procedures, within 24 hours prior to the first study treatment. 9. Previous exposure to murine CA-125 antibody (only applicable to those patients with nonmeasurable disease by RECIST). 10. Current or recent (within 10 days prior to the first study drug dose) chronic daily treatment with aspirin (>325 mg/day). 11. Current or recent treatment with another investigational drug and/or participation in another investigational study within 30 days of first study treatment dosing or earlier participation in this study. 12. Chronic daily treatment with corticosteroids (dose >10 mg/day methylprednisolone equivalent), excluding inhaled steroids. Laboratory: 13. Inadequate bone marrow function ANC: <1.5 x 109/l, or platelet count <100 x 109/l, or haemoglobin <9 g/dl. Patients may be transfused to maintain haemoglobin values >9 g/dl. 14. Inadequate coagulation parameters: aPTT >1.5 x ULN (patients on heparin treatment must have an aPTT between 1.5 - 2.5 x ULN), or INR >1.5. (In patients receiving anticoagulants (such as warfarin) INR must be between 2.0 and 3.0 in two consecutive measurements 1-4 days apart). 15. Inadequate liver function, defined as: serum (total) bilirubin >1.5 x ULN for the institution alkaline phosphatase, AST/SGOT or ALT/SGPT >2.5 x ULN (or 5 x ULN in the presence of liver metastases). 16. Inadequate renal function, defined as serum creatinine >2.0 mg/dl or >177 &#956;mol/l or calculated creatinine clearance <40ml/min (by Cockroft & Gault formula) for patients intended to be treated with topotecan. urine dipstick for proteinuria >2+. Patients with &#8805; 2+ proteinuria on baseline dipstick analysis should undergo a 24-hour urine collection and must demonstrate &#8804; 1 g of protein in the 24- hour urine. Alternatively, proteinuria testing can be performed according to local standards. Prior or concomitant conditions or procedures: 17. History or evidence upon physical / neurological examination of CNS disease unrelated to cancer, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures). 18. Symptomatic CNS metastasis 19. Pre-existing peripheral neuropathy &#8805; CTC grade 2. 20. Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days (with a confirmatory urine pregnancy test within 7 days prior to study treatment start). Et al. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable is progression-free survival (PFS). It is defined as the time from the date of randomisation to the first documented disease progression or death, whichever occurs first. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tollerabilita`; analisi dei biomarker (CA-125); qualita` della vita. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Chemioterapia standard prescelta. |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 111 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |